革蘭氏陽性、陰性菌、立克次氏體及巨型濾過性病毒等引起之感染症 Treatment of infections caused by Gram-positive or -negative bacteria and Rickettsiae
藥理
Tetracycline antibiotic Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; cell wall synthesis is not affected
藥動學
Distribution: 1. Widely distributed to most body fluids, bile, and tissues; poor CNS penetration; deposits in fat for extended periods; Vd: 0.14 to 0.7 L/kg 2. Protein binding: 55% to 96% Metabolism: 1. Hepatic to inactive metabolites 2. Bioavailability: 90% to 100% Half-life elimination: 1. General: 15 to 23 hours 2. Hepatic impairment: 11 to 16 hours 3. Renal impairment: 18 to 69 hours Excretion: Urine (5% to 12% excreted unchanged); feces (20% to 34%)
禁忌症
1. Hypersensitivity to minocycline, other tetracyclines, or any component of the formulation 2. Severe liver disease 3. Complete renal failure 4. Myasthenia gravis 5. Use in children <13 years of age; pregnancy; breastfeeding
懷孕分類
Minocycline crosses the placenta. Tetracycline-class antibiotics may cause fetal harm following maternal use in pregnancy.
哺乳分類
Minocycline is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk and the benefits.